Welcome to our dedicated page for Arcturus Therape SEC filings (Ticker: ARCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcturus Therapeutics Holdings Inc. filings document the regulatory record for a Nasdaq-listed commercial mRNA medicines and vaccines company with common stock registered under the symbol ARCT. Its Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations, and clinical or product disclosures tied to programs such as LUNAR-CF and KOSTAIVE.
The company’s proxy materials describe annual meeting matters, director elections, executive compensation, governance practices, and stockholder voting procedures. Other filings cover officer and board changes, registered security details, reporting-status notices such as Form 12b-25 notifications, and risk, capital-structure, collaboration, and development-stage disclosure relevant to its RNA therapeutics and vaccine business.
Arcturus Therapeutics Holdings Inc. (ARCT) reporting person Andy Sassine, who is identified as both a Director and the Chief Financial Officer, executed a purchase under the companys 2020 Employee Stock Purchase Plan on 08/15/2025. The filing states 1,238 shares were purchased at an effective price of $16.558, which the filer explains was based on 85% of the closing price on that date. Following the reported transaction the filing lists 221,764 shares beneficially owned. The Form 4 is signed by an attorney-in-fact, Ilan Katz, dated 08/19/2025.
Arcturus reported lower collaboration-driven revenue as its COVID-19 vaccine transitioned to commercialization, while advancing clinical programs and recognizing milestone payments.
Total revenue for the quarter was $28.3 million versus $49.9 million a year earlier, driven by $24.4 million of collaboration revenue from CSL Seqirus and $3.8 million of grant revenue from BARDA. Net loss was $9.18 million for the quarter and $23.26 million for the six months. Cash and restricted cash totaled $253.4 million, and the accumulated deficit was $472.1 million.
The company highlighted regulatory and commercial progress for KOSTAIVE (ARCT-154) with approvals in Japan and the EU, receipt of a $200.0 million upfront payment from CSL and approximately $509.7 million of total upfronts and milestones to date, including a $20.0 million development milestone recognized this quarter. Research and development and general and administrative expenses declined year-over-year as programs shifted toward commercialization.
Arcturus Therapeutics furnished a press release reporting its financial results for the quarter ended June 30, 2025 and provided a corporate update; the press release is furnished as Exhibit 99.1 and the company states the information is furnished (not filed) with customary forward-looking statements.
The filing highlights program and regulatory topics discussed in the press release, including ARCT-032 (Phase 2 cystic fibrosis study), ARCT-810 (Phase 3 design discussions), partnered COVID-19 and seasonal flu programs with CSL Seqirus, a BARDA-supported pandemic flu Phase 1 study, and regulatory filings and potential approvals related to KOSTAIVE with CSL and Meiji Seika Pharma and a planned U.S. BLA filing. The company disclaims any obligation to update forward-looking statements.
Schedule 13G/A (Amendment 8) filed on 07/30/2025 discloses that ARK Investment Management LLC and its CEO/CIO Catherine D. Wood collectively hold a significant position in Arcturus Therapeutics Holdings Inc. (ARCT).
- Shares beneficially owned: 1,715,040 common shares.
- Ownership percentage: 6.32 % of ARCT’s outstanding stock.
- Voting & dispositive power: ARK has sole voting and dispositive power over the full position; Wood has shared power through her control of ARK.
- Form type of filer: ARK is an investment adviser (IA); Wood is reported as a holding-company/control person (HC, IN).
- Client concentration: The ARK Genomic Revolution ETF is the only ARK client with an interest >5 % of ARCT.
The filing states the shares were acquired and are held in the ordinary course of business and not with the intent to influence control of the issuer.